Feedback / Questions
MYL-1401A (adalimumab biosimilar) - Mylan, Biocon, AbbVie
Biocon: Investor Presentation
(Biocon)
-
Nov 20, 2016 -
Anticipated US/EU filing in chronic plaque psoriasis in FY 2017
Anticipated BLA • Anticipated EU regulatory
•
Biosimilar • Psoriasis
http://www.biocon.com/docs/IR_PPT_Nov_2016.pdf
Nov 20, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious